Patent ID: 6194384
Filing Date: 2001-02-27
Classification: A61K,Y10S

Abstract:
A long-acting galenical formulation comprising about 1 to about 100 mg of a GRF compound having the activity of that of GRF, wherein said GRF compound is of the formula (I):Ra--X (I)wherein Ra is:one element selected from a cis or a trans enantiomer or a racemic mixture of: ##STR3## ##STR4##wherein R is a hydrogen or a lower alkyl; andX is a GRF peptide selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, wherein said GRF compound is pressed from about 1 to about 100 kg/mm.sup.2 in a tablet for parenteral administration, whereby said GRF compound is released as the tablet is eroded.